title: Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy.
authors.affiliation: Melanoma Institute Australia, North Sydney, New South Wales.
authors.forename: A
authors.initials: A
authors.lastname: Hoadley
authors.affiliation: Department of Gastroenterology, Royal North Shore Hospital, St. Leonards, New South Wales, Australia.
authors.forename: N
authors.initials: N
authors.lastname: Sandanayake
authors.affiliation: Melanoma Institute Australia, The University of Sydney and Royal North Shore Hospital, Australia.
authors.forename: G V
authors.initials: GV
authors.lastname: Long
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage / Q000009:adverse effects*; D010188:Exocrine Pancreatic Insufficiency / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000276:immunology; D006801:Humans; D000074324:Ipilimumab / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; D000074324:Ipilimumab; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab